Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. The company offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, SARS-CoV-2 respiratory plus, coronavirus, atypical respiratory, pertussis and PCP, parainfluenza 4, STI genital pathogen, extended spectrum beta-lactamase and carbapenemase producing organisms, viral meningitis, flavivirus dengue alphavirus, flavivirus reflex, dengue typing, and alphavirus reflex Detection kits under the EasyScreen name. Genetic Signatures Limited was incorporated in 2001 and is headquartered in Newtown, Australia.
| 0.685 | |
| 0.68 | |
| - | |
| 0.685 | |
| 0.68 | |
| 0.38-0.85 | |
| 159 M | |
| 227 M | |
| 13 768 K | |
| 0.046 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
It hasn't been the best quarter for Genetic Signatures Limited (ASX:GSS) shareholders, since the share price has fallen 22% in that time. But that doesn't change the fact that shareholders have receiv...
When close to half the companies in Australia have price-to-earnings ratios (or "P/E's") below 14x, you may consider Genetic Signatures Limited (ASX:GSS) as a stock to avoid entirely with its 76.9x P/...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
